eJHaem (May 2023)

Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype

  • Mar Mallo,
  • Heinz Tuechler,
  • Leonor Arenillas,
  • Sophie Raynaud,
  • Thomas Cluzeau,
  • Lee‐Yung Shih,
  • Chiang Tung‐Liang,
  • Christina Ganster,
  • Katayoon Shirneshan,
  • Detlef Haase,
  • Martí Mascaró,
  • Laura Palomo,
  • José Cervera,
  • Esperanza Such,
  • Nicola Trim,
  • Sally Jeffries,
  • Emma Ridgway,
  • Giovanni Marconi,
  • Giovanni Martinelli,
  • Francesc Solé

DOI
https://doi.org/10.1002/jha2.651
Journal volume & issue
Vol. 4, no. 2
pp. 446 – 449

Abstract

Read online

Abstract Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20–30% with the complementary application of genomic microarrays. We here present a multicenter collaborative study of 163 MDS cases with a normal karyotype (≥10 metaphases) at diagnosis. All cases were analyzed with the ThermoFisher® microarray (either SNP 6.0 or CytoScan HD) for the identification of both copy number alteration(CNA) and regions of homozygosity (ROH). Our series supports that 25 Mb cut‐off as having the most prognostic impact, even after adjustment by IPSS‐R. This study highlights the importance of microarrays in MDS patients, to detect CNAs and especially to detect acquired ROH which has demonstrated a high prognostic impact.

Keywords